98
Participants
Start Date
April 16, 2019
Primary Completion Date
January 10, 2023
Study Completion Date
January 10, 2023
TJ011133
TJ011133 will be administered weekly.
Pembrolizumab
Pembrolizumab will be administered every 3 weeks.
Rituximab
Rituximab will be administered weekly for 5 doses, then followed by monthly doses.
NYU Langone Health, New York
Mayo Clinic, Jacksonville
University of Alabama - Birmingham, Birmingham
Vanderbilt-Ingram Cancer Center, Nashville
Horizon Oncology, Lafayette
University of Michigan, Ann Arbor
Henry Ford Cancer Institute/Henry Ford Hospital, Detroit
The Fourth Hpspital of Hebei Medical University(Hebei Cancer Hospital), Shijiazhuang
Mayo Clinic, Rochester
Mayo Clinic, Scottsdale
Seattle Cancer Care Alliance, Seattle
Beijing Cancer Hospital, Beijing
The Second Hospital of Dalian Medical University, Dalian
Fudan University Shanghai Cancer Center, Shanghai
Tianjin Medical University Cancer Institute & Hospital, Tianjin
Zhejiang Cancer Hospital, Hangzhou
HuBei Cancer Hospital, Wuhan
Henan Cancer Hospital, Zhengzhou
Sun Yat-sen University Cancer Center, Guangzhou
Yale School of Medicine, New Haven
Rutgers Cancer Institute of New Jersey, New Brunswick
Lead Sponsor
Merck Sharp & Dohme LLC
INDUSTRY
I-Mab Biopharma US Limited
INDUSTRY